New clinical trial designs for evaluation of antimicrobial agents
- David Paterson, Director, University of Queensland Centre for Clinical Research (Australia)
- Julie Marsh, Biostatistical Lead, Wesfarmers Centre of Vaccines and Infectious Diseases, University of Western Australia (Australia)
Moderator: Tom Snelling, Professor of Infectious Diseases and Director of the Health and Clinical Analytics lab, Sydney School of Public Health, University of Sydney (Australia)
Presentation 1: Overview of innovations in clinical trials of antimicrobial agents (David Paterson)
- The value proposition of clinical trial networks
- What could MAMS, DOOR or PRACTical bring to clinical trials of antimicrobials?
- Pros and cons of new clinical trial designs
Presentation 2: Overview of adaptive trials in vaccines & antimicrobial agents (Julie Marsh)
- Adaptive trials
- Understanding the decision process for trial adaptations
- Implementation challenges
- Trial governance & integrity
This live webinar including interactive Q&A session will be broadcast on 27 May 2021 at 9:30-11:00 CEST. Find your time zone here.
If you have questions or comments, please let us know: firstname.lastname@example.org.
In our Antimicrobial Viewpoints series, we invite experts of different aspects of antimicrobial resistance (AMR) to share their knowledge and opinions about the current status and the future challenges of this field. Our latest articles can be found below:
- Introducing ProMED-AMR, the new ProMED network for antimicrobial resistance by Matthew E. Levison
Causes of antibiotic shortages and the solutions to address them by Enrico Baraldi
- Monitoring antimicrobial resistance in Ghana: a focus on the hospital environment by Abiola Isawumi and Lydia Mosi